Smith & Nephew's Investments Hit Bottom Line

Smith & Nephew’s investing activities may continue to induce short-term profitability pressures but provide key long-term growth opportunities

Julie Stralow, CFA 8 August, 2011 | 11:47AM
Facebook Twitter LinkedIn

Smith & Nephew's (SN.) momentum continued in the second quarter. While we've trimmed our near-term outlook primarily for potential regulatory changes in the United States, that factor was offset by cash flow generated since our last major update. We're maintaining our fair value estimate.

During the quarter, sales grew 12% (5% in constant currency) to about $1.1 billion. The orthopedic segment grew 4% in constant currency, outpacing the market thanks to momentum in knees with the Verilast technology.

Profitability remained weak, as investing activities and mix issues (higher growth from relatively low-margin products) outweighed efficiency gains. These factors may weigh on results for the next several quarters, especially as the firm implements some strategic changes under its new CEO. However, while initiatives such as creating emerging markets and international divisions may induce short-term profitability pressures, they could provide key growth in the long run, as developed markets become more difficult to operate in and mature.

For the entire note and research report, click here.

Morningstar's Equity Analyst Notes and Equity Research Reports contain our independent view on a company's investment case, valuation, financial health and stewardship, and are available to Premium subscribers.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Smith & Nephew PLC1,180.50 GBX-0.80Rating

About Author

Julie Stralow, CFA  Julie Stralow, CFA, is a senior securities analyst with Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures